Updated on 22 October 2014
GVK said that this will further enhance the pipeline of customers and collaborators
Singapore: GVK biosciences has announced the successful completion of in-silico based alternative indications of shelved compounds using GVK BIO's proprietary Drug Re-purposing platform for Takeda pharmaceutical company.
The company also announced plans of further partnership with Takeda to evaluate the pre-clinical proof-of-concept for certain indications of selected therapeutic compounds. They will also develop novel indications for the previously failed compounds.
Leveraging its experience and expertise, GVK Bio has developed a unique Drug Re-purposing Platform called GRIP (GVK BIO Re-purposing Integrated Platform).
GRIP is a combination of proprietary Re-purposing Database, eight different algorithms, analytical tools and a visualization engine.
Mr Sreeni Devidas, vice president, Business Development, GVK BIO, said that the success of the project with Takeda illustrated the value add that this approach brought to further enhance the pipeline of customers and collaborators.
Mr Nandu Gattu, vice president,Drug Re-purposing at GVK BIO, said, "GVK BIO is well known for its rich and extensive biological, chemical and clinical databases. We have developed a collaborated platform of computational algorithms, analytical capabilities and our custom curated databases. GVK's expertise in drug discovery enables us to develop a multi-pronged approach resulting in higher success rates."